Details for Patent: 8,791,140
✉ Email this page to a colleague
Which drugs does patent 8,791,140 protect, and when does it expire?
Patent 8,791,140 protects INLYTA and is included in one NDA.
Protection for INLYTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-three patent family members in twenty-three countries.
Summary for Patent: 8,791,140
| Title: | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals |
| Abstract: | The present invention relates to crystalline polymorphic and amorphous form of 6-[2-(methylcarbamoyl)phenyl sulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one polymorphic form and to the therapeutic or prophylactic use of such polymorphic forms and compositions. |
| Inventor(s): | Campeta; Anthony Michael (Ledyard, CT), Chekal; Brian Patrick (Niantic, CT), Singer; Robert Alan (Niantic, CT) |
| Assignee: | Pfizer Inc. (New York, NY) |
| Application Number: | 12/594,575 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,791,140 |
|
Patent Claim Types: see list of patent claims | Compound; |
Recent additions to Drugs Protected by US Patent 8,791,140
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pf Prism Cv | INLYTA | axitinib | TABLET | 202324 | Jan 27, 2012 | RX | Yes | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 8,791,140
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pf Prism Cv | INLYTA | axitinib | TABLET;ORAL | 202324-001 | Jan 27, 2012 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Pf Prism Cv | INLYTA | axitinib | TABLET;ORAL | 202324-002 | Jan 27, 2012 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,791,140
| PCT Information | |||
| PCT Filed | March 25, 2008 | PCT Application Number: | PCT/IB2008/000792 |
| PCT Publication Date: | October 16, 2008 | PCT Publication Number: | WO2008/122858 |
International Family Members for US Patent 8,791,140
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 065931 | ⤷ Sign Up | |||
| Australia | 2008236444 | ⤷ Sign Up | |||
| Brazil | PI0809471 | ⤷ Sign Up | |||
| Canada | 2682859 | ⤷ Sign Up | |||
| China | 101679356 | ⤷ Sign Up | |||
| China | 103626739 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
